GLP-1 derivatives modified with zwitterionic peptides, their preparation methods and applications

By linking zwitterionic peptides to GLP-1 derivatives to form nanomicelle solutions, the problems of immune response and adverse reactions of existing GLP-1 analog drugs are solved, and a long-lasting hypoglycemic effect is achieved.

CN110862448BActive Publication Date: 2026-11-17ZHEJIANG UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN201911160129.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-11-21
Publication Date
2026-11-17
Estimated Expiration
2039-11-21

AI Technical Summary

Technical Problem

Existing GLP-1 analog drugs have problems with immune response, adverse reactions and unstable blood drug concentration, making it difficult to achieve long-term blood glucose lowering effects.

Method used

By linking zwitterionic peptides, especially poly(L-glutamyl-L-lysine) zwitterionic peptides, to GLP-1 derivatives to form click reaction sites, and preparing nanomicelle solutions under physiological conditions, long-term sustained release can be achieved.

Benefits of technology

It achieves more stable in vivo sustained release, long circulation capacity, low immunogenicity and low tissue rejection, reduces adverse reactions, and has a long-lasting hypoglycemic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN110862448B_ABST
    Figure CN110862448B_ABST
Patent Text Reader

Abstract

This invention discloses a zwitterionic peptide-modified GLP-1 derivative, its preparation method, and its applications. It involves attaching a zwitterionic peptide to the reactive site of a GLP-1 derivative. Specifically, the zwitterionic peptide is linked to the click-reactive site in the GLP-1 derivative, and the zwitterionic peptide contains poly(L-glutamyl-L-lysine), which contains a reactive group linked to the click-reactive site. The zwitterionic peptide-modified GLP-1 derivative of this invention can be used to prepare long-acting blood glucose control drugs for type II diabetes patients. Compared with existing GLP-1 drugs, it exhibits more stable in vivo sustained release, superior long-term blood circulation capacity, lower tissue rejection, lower immunogenicity, excellent tissue compatibility, in vivo enzymatic degradation, and normal metabolic capacity. It is less likely to induce hypoglycemia and adverse gastrointestinal reactions, and can avoid injection site nodules.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a glucagon-like peptide-1 (GLP-1) derivative, its preparation method, and its application in the preparation of drugs. Background Technology

[0002] GLP-1 belongs to the incretin family and has a glucose concentration-dependent hypoglycemic effect. It can enhance β-cell response, reduce glucagon secretion by acting on α-cells, and suppress appetite and slow gastric emptying by acting on the feeding center and stomach, thereby reducing β-cell load. GLP-1 secretion is significantly reduced in patients with type 2 diabetes (T2D), making it an important therapeutic target. However, after entering the human body, GLP-1 is rapidly degraded by the widely distributed dipeptidyl peptidase-4 (DPP-4), with a half-life of only 12 minutes. Therefore, the development of novel GLP-1 analogues is of great significance.

[0003] Currently available GLP-1 analogs mainly include liraglutide, exenatide, lixinatide, duraglutide, abiglutide, polylactic acid-encapsulated exenatide, semaglutide, and polyethylene glycol-modified loxenatide. GLP-1 analog drugs have evolved from once-daily formulations to long-acting formulations; the first three are 1-day, 2-day, and 2-day formulations, respectively, while the latter five are weekly formulations. They achieve weekly formulations through methods such as antibody Fc fragment fusion, albumin fusion, polylactic acid encapsulation, C18 fatty acid diacid modification with albumin binding, and PEGylation. Their mechanisms are mainly divided into two categories: 1) polylactic acid microspheres encapsulating exenatide to maintain blood drug concentration through subcutaneous sustained release; and 2) duraglutide, abiglutide, semaglutide, and polyethylene glycol-modified loxenatide, which achieve subcutaneous sustained release followed by long-term circulation in the blood. Due to the immune response to subcutaneously retained drugs, the aforementioned long-acting release formulations all face challenges related to immune reactions. Polylactic acid microspheres encapsulating exenatide cause significant adverse reactions at the injection site due to polylactic acid's allogeneic rejection. Duraglutide and abiglutide, based on fusion protein technology, exhibit high antigenicity due to the application of functional protein domains. Semaglutide, on the other hand, causes gastrointestinal discomfort and nausea similar to those experienced with short-acting liraglutide. PEGylated loxenatide utilizes PEG's anti-protein non-specific adsorption capacity and large hydrodynamic radius to prolong blood circulation time, but the widespread presence of PEG antibodies and PEG complement activation limit its applicability. Therefore, developing highly effective, low-immunogenic, stable blood drug concentrations, and low-gastrointestinal-reaction long-acting GLP-1 analogs is of great importance for the treatment of type II diabetes. Summary of the Invention

[0004] The purpose of this invention is to provide a novel GLP-1 derivative, its preparation method, and a type II diabetes drug prepared therefrom. This derivative is modified with a zwitterionic polypeptide, exhibiting good controlled-release properties, achieving a long-lasting hypoglycemic effect, and is less likely to induce hypoglycemia and adverse gastrointestinal reactions.

[0005] To achieve the above-mentioned objectives, the technical solution adopted by the present invention is as follows: the zwitterionic peptide-modified GLP-1 derivative of the present invention has a zwitterionic peptide linked to the reaction site of the GLP-1 derivative.

[0006] Furthermore, the present invention involves linking the zwitterionic polypeptide to the click reaction site of the GLP-1 derivative, wherein the zwitterionic polypeptide contains poly(L-glutamyl-L-lysine), and the poly(L-glutamyl-L-lysine) contains a reactive group that is linked to the click reaction site.

[0007] Furthermore, the zwitterionic polypeptide of the present invention has a thiol group or a double bond at its end.

[0008] Furthermore, the zwitterionic peptide-modified GLP-1 derivative of the present invention has a structure as shown in any one of structural formulas I to III:

[0009]

[0010]

[0011] The present invention provides a method for preparing a zwitterionic peptide-modified GLP-1 derivative as shown in structural formula I, comprising:

[0012] Using Nα-(δ-benzyl-L-glutamyl)-Nε-benzyloxycarbonyl-L-lysine as a monomer, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride as condensing agents, and N-tert-butoxycarbonyl-S-triphenylmethyl-L-cysteine ​​as a capping agent, polymerization was carried out followed by deprotection to obtain an L-cysteine-capped zwitterionic polypeptide. The ε-amino group of the lysine residue in the GLP-1 derivative, whose terminal amino group was protected by fluorene methoxycarbonyl, was modified with maleic anhydride and linked to the thiol group of the L-cysteine-capped zwitterionic polypeptide. Then, the fluorene methoxycarbonyl group was removed under alkaline conditions.

[0013] Furthermore, the L-cysteine-terminated zwitterionic polypeptide of the present invention has a molecular weight of 5–100 kDa.

[0014] Furthermore, the L-cysteine-terminated zwitterionic polypeptide of the present invention has a molecular weight of 10 kDa.

[0015] One application of the zwitterionic peptide-modified GLP-1 derivative of the present invention is: the zwitterionic peptide-modified GLP-1 derivative is used to prepare a drug for type II diabetes.

[0016] A type II diabetes drug made from a GLP-1 derivative modified with a zwitterionic peptide of the present invention, wherein the active pharmaceutical ingredient of the drug is the GLP-1 derivative modified with the zwitterionic peptide, or the active pharmaceutical ingredient of the drug contains the GLP-1 derivative modified with the zwitterionic peptide.

[0017] Furthermore, the drug of the present invention is an injectable preparation made from a phosphate buffer solution with a physiological concentration of pH 7.4.

[0018] Compared with the prior art, the beneficial effects of the present invention are: the zwitterionic peptide-modified GLP-1 derivative of the present invention has more stable in vivo sustained release, excellent long blood circulation ability, lower tissue rejection, low immunogenicity, better tissue compatibility, in vivo enzyme degradation and normal metabolic ability, and is less likely to cause hypoglycemia and adverse gastrointestinal reactions. It can also avoid injection site nodules and other characteristics, which are of great significance for the treatment of type II diabetes. Attached Figure Description

[0019] Figure 1 For poly(EK)-Arg 34 Lys 26 The effect of GLP-1 [7-37] on insulin secretion by pancreatic β cells;

[0020] Figure 2 A single subcutaneous injection of poly(EK)-Arg 34 Lys 26 Changes in blood glucose concentration after administration of GLP-1 [7-37] (315 nM / kg), liraglutide (105 nM / kg), and PBS, with fasting for 6 hours prior to blood glucose measurement;

[0021] Figure 3 Label Cy5.5 as poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] retention at the injection site in rats (taking rats 18 and 19 as examples);

[0022] Figure 4 For poly(EK)-Arg 34 Lys 26 Immunogenicity of GLP-1 [7-37] at the injection site in rats (using rats 1 and 6 as examples). Detailed Implementation

[0023] The following examples utilize a click reaction to link a zwitterionic peptide containing poly(L-glutamyl-L-lysine) at a specific site on a GLP-1 derivative (whose amino acid sequence is shown in SEQ ID No. 1 or SEQ ID No. 2). This click reaction at a specific site can be achieved by constructing the necessary functional group pairs for the click reaction at the end groups of the GLP-1 derivative and the zwitterionic peptide containing poly(L-glutamyl-L-lysine). Furthermore, utilizing the strong hydration capacity of the zwitterionic peptide, the resulting zwitterionic peptide-modified GLP-1 derivative can be formulated into a nanomicelle solution under physiological solution conditions and directly administered subcutaneously as an injection to achieve a long-term blood glucose-lowering effect in type 2 diabetic patients. Simultaneously, the zwitterionic peptide containing poly(L-glutamyl-L-lysine) exhibits excellent resistance to non-specific protein adsorption, resulting in lower tissue rejection, lower immunogenicity, better tissue compatibility, and improved in vivo enzymatic degradation and normal metabolic capacity in the modified GLP-1 derivative.

[0024] The present invention will be further described in detail below with reference to specific embodiments.

[0025] (I) Synthesis of Compounds

[0026] Example 1

[0027] (1) Prepare cysteine-terminated poly(L-glutamyl-L-lysine) zwitterionic polypeptide poly(EK)-Cys (compound 3) according to the following synthetic route a:

[0028]

[0029] Synthetic route a

[0030] The structural formulas of compounds 1, 2, and 3 are shown below:

[0031]

[0032]

[0033] Nα-(δ-benzyl-L-glutamyl)-Nε-benzyloxycarbonyl-L-lysine (compound 1) (0.2 g, 0.4 mmol), Boc-Cys(Trt)-OH (0.9 mg, 0.002 mmol), EDC·HCl (0.12 g, 0.6 mmol), and HOBt (0.08 g, 0.6 mmol) were added to 1 mL of DMF and reacted under sealed conditions at room temperature for 48 h. Then, 8–10 times the volume of 4°C diethyl ether was added to the reaction solution, and the precipitate obtained by centrifugation was compound 2. Compound 2 was used directly in the next reaction without purification. Compound 2 was dissolved in 2 mL of TFA, and then 4 mL of 33 wt% HBr / HOAc was added, and the reaction was allowed to proceed for approximately 6 h. After the reaction was complete, the reaction solution was added dropwise to 4°C diethyl ether to obtain a precipitate. The precipitate was dissolved in an appropriate amount of water, and the pH was adjusted to 7-8 by adding a saturated sodium bicarbonate solution dropwise. After dialyzing, the white solid poly(EK)-Cys (compound 3) was obtained by freeze-drying.

[0034] It should be noted that by adjusting the feed ratio of Nα-(δ-benzyl-L-glutamyl)-Nε-benzyloxycarbonyl-L-lysine (EK-dimer) and Boc-Cys(Trt)-OH, poly(EK)-Cys (compound 3) with different molecular weights can be obtained, as shown in Table 1.

[0035] Table 1. Molecular weights and reaction yields of different target peptides corresponding to different EK-dimer and Boc-Cys(Trt)-OH feed ratios.

[0036]

[0037] (2) Synthesize the GLP-1 derivative poly(EK)-Arg modified with poly(L-glutamyl-L-lysine) zwitterionic peptide according to the following synthetic route b. 34 Lys 26 -GLP-1[7-37](Compound 6):

[0038]

[0039] Synthetic route b

[0040] The structural formulas of compounds 4, 5, and 6 are shown below:

[0041]

[0042]

[0043] (2.1)Arg 34 Lys 26Synthesis of -GLP-1[7-37]-MA (compound 5):

[0044] Dissolve Fmoc-Arg in 80 μL of anhydrous DMSO 34 Lys 26 -GLP-1[7-37] (compound 4, whose amino acid sequence is shown in SEQ ID No. 1) (0.02 g, 5.5 mmol) was dissolved in 120 μL of anhydrous DMSO to dissolve maleic anhydride (0.016 g, 160 mmol) for later use. Then, the anhydrous DMSO solution of compound 4 was slowly added dropwise to the anhydrous DMSO solution of maleic anhydride, and the reaction was carried out under stirring and sealed at room temperature for 24 h. After dialyzing, the mixture was lyophilized to obtain a white powder Arg. 34 Lys 26 -GLP-1[7-37]-MA (compound 5).

[0045] (2.2)poly(EK)-Arg 34 Lys 26 Synthesis of -GLP-1[7-37](compound 6):

[0046] Compound 5 was dissolved in 1 ml of DMSO, and the pH was adjusted to approximately 6.0 with TFA. Poly(EK)-Cys was dissolved in an appropriate amount of water, and the pH was adjusted to approximately 6.0 with TFA. The aqueous solution of poly(EK)-Cys was added dropwise to the DMSO solution of compound 5, and the reaction was carried out under stirring and sealed at room temperature for 24 h. After the reaction was complete, the solution was diluted with water and lyophilized to obtain a white powder. The Fmoc protecting group on the peptide was removed using a 50% dichloromethane solution of piperidine, followed by dialysis and lyophilization to obtain poly(EK)-Arg. 34 Lys 26 -GLP-1[7-37](compound 6), which has the structure shown in structural formula I.

[0047] Example 2

[0048] (1) Synthesize 11-maleamidoundecanoic acid-terminated poly(L-glutamyl-L-lysine) zwitterionic polypeptide poly(EK)-KMUA (compound 8) according to the following synthetic route c:

[0049]

[0050] Synthesis route c

[0051] The structural formulas of compounds 7 and 8 are shown below:

[0052]

[0053]

[0054] Nα-(δ-benzyl-L-glutamyl)-Nε-benzyloxycarbonyl-L-lysine (compound 1) (0.2 g, 0.4 mmol), 11-maleamidoundecanoic acid (KMUA) (0.56 mg, 0.002 mmol), EDC·HCl (0.12 g, 0.6 mmol), and HOBt (0.08 g, 0.6 mmol) were added to 1 mL of DMF and reacted under sealed conditions at room temperature for 48 h. Then, 8–10 times the volume of 4°C diethyl ether was added to the reaction solution, and the precipitate obtained by centrifugation was compound 7. Compound 7 was used directly in the next reaction without purification. Compound 7 was dissolved in 2 mL of TFA, and then 4 mL of 33 wt% HBr / HOAc was added, and the reaction was allowed to proceed for approximately 6 h. After the reaction was complete, the reaction solution was added dropwise to 4°C diethyl ether to obtain a precipitate. The precipitate was dissolved in an appropriate amount of water, and the pH was adjusted to 7-8 by adding a saturated sodium bicarbonate solution dropwise. After dialyzing and freeze-drying, a white solid poly(EK)-KMUA (compound 8) was obtained.

[0055] It should be noted that by adjusting the feed ratio of Nα-(δ-benzyl-L-glutamyl)-Nε-benzyloxycarbonyl-L-lysine (compound 1) and 11-maleamidoundecanoic acid, poly(EK)-KMUA (compound 8) with different molecular weights can be obtained.

[0056] (2) Synthesize poly(EK)-Arg according to the following synthetic route d 34 Cys 26 -GLP-1[7-37](Compound 10):

[0057]

[0058] Synthesis route d

[0059] The structural formulas of compounds 9 and 10 are shown below:

[0060]

[0061] Dissolve Fmoc-Arg in 1 ml of DMSO 34 Cys 26-GLP-1[7-37] (compound 9, whose amino acid sequence is shown in SEQ ID No. 2) was added, and the pH was adjusted to approximately 6.0 with TFA. Poly(EK)-KMUA (compound 8) was dissolved in an appropriate amount of water, and the pH was adjusted to approximately 6.0 with TFA. The aqueous solution of poly(EK)-KMUA was added dropwise to the DMSO solution of compound 9, and the reaction was carried out under stirring and sealed at room temperature for 24 h. After the reaction was completed, the solution was diluted with water and lyophilized to obtain a white powder. The Fmoc protecting group on the peptide was removed using a 50% dichloromethane solution of piperidine, dialyzed, and lyophilized to obtain poly(EK)-Arg. 34 Cys 26 -GLP-1[7-37](compound 10), which has the structure shown in structural formula II.

[0062] Example 3

[0063] (1) In this embodiment, the 11-maleamidoundecanoic acid-terminated poly(L-glutamyl-L-lysine)(L-aspartic acid) zwitterionic polypeptide poly(EK)(D)-KMUA (compound 12) was synthesized according to the following synthetic route e:

[0064]

[0065] Synthetic route e

[0066] The structural formulas of compounds 11 and 12 are shown below:

[0067]

[0068] Nα-(δ-benzyl-L-glutamyl)-Nε-benzyloxycarbonyl-L-lysine (compound 1) (0.2 g, 0.4 mmol), L-aspartic acid benzyl ester (0.02 g, 0.1 mmol), 11-maleamidoundecanoic acid (0.56 mg, 0.002 mmol), EDC·HCl (0.12 g, 0.6 mmol), HOBt (0.08 g, 0.6 mmol), N,N-diisopropylethylamine (0.19 g, 1.5 mmol), and tripyrrolylphosphonium hexafluorophosphate bromide (0.33 g, 0.7 mmol) were added to 1 mL of DMF and reacted under sealed conditions at room temperature for 48 h. Then, 8–10 times the volume of diethyl ether at 4 °C was added to the reaction solution, and the precipitate was collected by centrifugation. The precipitate was washed 2–3 times with 8–10 times the volume of methanol to obtain compound 11. Compound 11 was used directly in the next reaction without purification. Compound 11 was dissolved in 2 ml of TFA, and then 4 ml of 33 wt% HBr / HOAc was added. The reaction was allowed to proceed for about 6 hours. After the reaction was completed, the reaction solution was added dropwise to diethyl ether at 4°C to obtain a precipitate. The precipitate was dissolved in an appropriate amount of water, and the pH was adjusted to 7-8 by adding saturated sodium bicarbonate solution. The solution was dialyzed and lyophilized to obtain a white solid poly(EK)(D)-KMUA (compound 12).

[0069] (2) Synthesize poly(EK)(D)-Arg according to the following synthetic route f 34 Cys 26 Synthesis of -GLP-1[7-37](compound 13):

[0070]

[0071] Synthetic route f

[0072] The structural formula of compound 13 is shown below:

[0073]

[0074] Dissolve Fmoc-Arg in 1 ml of DMSO 34 Cys 26 -GLP-1[7-37](compound 9), with TFA added to adjust the pH to approximately 6.0. Poly(EK)-KMUA was dissolved in an appropriate amount of water, and the pH was adjusted to approximately 6.0 with TFA. The aqueous solution of poly(EK)-KMUA was added dropwise to the DMSO solution of compound 9, and the reaction was carried out under stirring and sealed at room temperature for 24 hours. After the reaction was completed, the solution was diluted with water and lyophilized to obtain a white powder. The Fmoc protecting group on the peptide was removed using a 50% dichloromethane solution of piperidine, dialyzed, and lyophilized to obtain poly(EK)(D)-Arg. 34 Cys 26-GLP-1[7-37](compound 13), which has the structure shown in structural formula III.

[0075] (ii) poly(EK)-Arg 34 Lys 26 In vitro activity assay of -GLP-1[7-37] (Structure I)

[0076] To investigate poly(EK)-Arg 34 Lys 26 The effect of GLP-1 [7-37] (poly(EK) molecular weight of 10 kDa) on insulin secretion by pancreatic β cells was investigated. 3rd-4th generation rat INS-1 cells were selected, and after resuscitation, they were cultured in 96-well plates for 24 h. The cell culture medium was then removed, washed three times with KRB buffer (Krebs-Ringer buffer), and incubated for 1 h with KRB buffer containing 3 mM glucose. Different concentration gradients of GLP-1 and poly(EK)-Arg were prepared using KRB buffer. 34 Lys 26 -GLP-1[7-37] solution. Take out the KRB buffer and add the prepared GLP-1 and poly(EK)-Arg solutions of different concentrations. 34 Lys 26 Incubate GLP-1[7-37] in KRB solution for 1 h. Collect cell suspension and use rat insulin ELISA kit to detect different concentrations of GLP-1 and poly(EK)-Arg. 34 Lys 26 -GLP-1 [7-37] reduces insulin secretion from pancreatic β cells. See details below. Figure 1 The results show poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] exhibits activity comparable to liraglutide in the physiological concentration range, but its activity decreases at higher concentrations. This may be related to the formation of nanomicelles, which restricts the free poly(EK)-Arg in the culture medium. 34 Lys 26 -GLP-1[7-37] concentration. This phenomenon helps avoid unnecessary high blood drug concentrations when administering large doses for long-acting drugs, and reduces patient discomfort at high blood drug concentrations.

[0077] (III) poly(EK)-Arg 34 Lys 26 The in vivo glucose-lowering effect of GLP-1[7-37] (structural formula I)

[0078] To investigate poly(EK)-Arg 34Lys 26 The in vivo hypoglycemic effect of poly(EK)-Arg-1[7-37] (poly(EK) molecular weight of 10 kDa) was investigated by selecting 15 successfully modeled type II diabetic SD rats and dividing them into three groups: A, B, and C. Among them, group A was poly(EK)-Arg-1[7-37] (poly(EK) molecular weight of 10 kDa). 34 Lys 26 -GLP-1[7-37] experimental group, group B is the liraglutide group, group C is the PBS group, as poly(EK)-Arg 34 Lys 26 -GLP-1 [7-37] control group for in vivo glucose-lowering effect. Preparation of 40 μM liraglutide and poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] injection. Among them, poly(EK)-Arg... 34 Lys 26 GLP-1 [7-37] was dispersed in a physiologically effective phosphate buffer solution at pH 7.4. Rats were shaved on the back and then injected subcutaneously. Group A received a dose of 315 nM / kg, and Group B received a dose of 105 nM / kg. Blood samples were collected and blood glucose levels were measured after administration. Rats were fasted for 6 hours before each blood collection. Specific results are detailed below. Figure 2 The results show poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] still had the ability to lower blood glucose levels in rats for 276 hours. However, in the liraglutide group, blood glucose levels exceeded the measurement limit only 36 hours later, indicating that poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] has the ability to lower blood glucose concentration over a long period of time.

[0079] (iv) poly(EK)-Arg 34 Lys 26 In vivo distribution of GLP-1 [7-37]

[0080] Dissolve 1.38 mg of Cy5.5-nhs active ester in 1 ml of DMSO, and take 50 μL for later use. Add poly(EK)-Arg... 34 Lys 26 -GLP-1[7-37] (poly(EK) molecular weight 10 kDa) was dissolved in 100 μL PBS (1×) and set aside. The DMSO solution of Cy5.5-nhs active ester was added dropwise to poly(EK)-Arg 34 Lys 26-GLP-1[7-37] was reacted in a PBS solution with shaking at 1000 rpm for 5 h, dialyzed, and lyophilized to obtain Cy5.5-labeled poly(EK)-Arg. 34 Lys 26 -GLP-1[7-37]. 40 μM Cy5.5-poly(EK)-Arg was prepared by dispersion in a physiologically adequate phosphate buffer solution at pH 7.4. 34 Lys 26 -GLP-1[7-37] injection. After shaving the back of rats, the drug was injected subcutaneously at a dose of 105 nM / kg. In vivo imaging was used to observe the drug's retention at the injection site on days 1, 2, 3, and 7 post-administration. Results showed that cy5.5 fluorescently labeled poly(EK)-Arg... 34 Lys 26 -GLP-1[7-37] can remain at the injection site for more than 7 days. See details below. Figure 3 This indicates that poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] can remain subcutaneously for a long time under the protection of poly(EK). This result supports the poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] has the ability to lower blood glucose concentration over a long period of time.

[0081] (V) poly(EK)-Arg 34 Lys 26 Immunogenicity detection of GLP-1 [7-37]

[0082] To investigate poly(EK)-Arg 34 Lys 26 Immunogenicity of GLP-1 [7-37] (poly(EK) molecular weight of 10 kDa) at the injection site was investigated in 10 successfully modeled type II diabetic SD rats, which were divided into two groups, A and B. Group A contained poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] experimental group, group B was the PBS group, as poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] Immunogenicity control at the injection site. 40 μM poly(EK)-Arg was prepared using physiologically adequate phosphate buffer solution at pH 7.4. 34 Lys 26-GLP-1[7-37] injection. After shaving the back of rats, subcutaneous injection was administered. Group A received a weekly dose of 105 nM / kg for 3 weeks. Three weeks later, the SD rats were dissected, and the injection site was fixed in formalin for approximately 24 hours. Paraffin sections were prepared, stained with hematoxylin-eosin (HE), and observed and images were acquired under a 10× and 40× objective microscope. The results showed poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] caused almost no inflammatory response at the injection site. See details below. Figure 4 This indicates that poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] retains the original poly(EK) anti-protein non-specific adsorption ability. This result supports the poly(EK)-Arg 34 Lys 26 -GLP-1[7-37] has lower tissue rejection and lower immunogenicity.

[0083] The above description is only a non-limiting embodiment of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the inventive concept of the present invention and without creative effort, and these all fall within the protection scope of the present invention. sequence list <110> Zhejiang University <120> GLP-1 derivatives modified with zwitterionic peptides, their preparation methods and applications <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> 31 <212> PRT <213> Artificial Sequence <400> 1 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly 20 25 30 <210> 2 <211> 31 <212> PRT <213> Artificial Sequence <400> 2 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1 5 10 15 Gln Ala Ala Cys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly 20 25 30

Claims

1. A zwitterionic peptide-modified GLP-1 derivative, characterized in that, It has a structure as shown in any one of structural formulas I to III: ; I ; ; Ⅱ; ; Ⅲ。 2. A method for preparing a zwitterionic polypeptide-modified GLP-1 derivative as shown in structural formula I of claim 1, characterized in that, include: Using Nα-(δ-benzyl-L-glutamyl)-Nε-benzyloxycarbonyl-L-lysine as a monomer, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride as condensing agents, and N-tert-butoxycarbonyl-S-triphenylmethyl-L-cysteine ​​as a capping agent, the L-cysteine-capped zwitterionic polypeptide was obtained by polymerization followed by deprotection. The ε-amino group of the lysine residue in the GLP-1 derivative, whose terminal amino group is protected by a fluorene methoxycarbonyl group, is modified with maleic anhydride and then linked to the thiol group of the L-cysteine-terminated zwitterionic polypeptide. The fluorene methoxycarbonyl group is then removed under alkaline conditions.

3. The preparation method according to claim 2, characterized in that: The L-cysteine-terminated zwitterionic polypeptide has a molecular weight of 5–100 kDa.

4. The preparation method according to claim 3, characterized in that: The L-cysteine-terminated zwitterionic polypeptide has a molecular weight of 10 kDa.

5. The application of the zwitterionic polypeptide-modified GLP-1 derivative according to claim 1, characterized in that: The zwitterionic peptide-modified GLP-1 derivative is used to prepare drugs for type II diabetes.

6. A type II diabetes drug made from a GLP-1 derivative modified with the zwitterionic polypeptide of claim 1, characterized in that: The active pharmaceutical ingredient of the drug is a GLP-1 derivative modified with the zwitterionic peptide, or the active pharmaceutical ingredient of the drug contains a GLP-1 derivative modified with the zwitterionic peptide.

7. The type II diabetes drug according to claim 6, characterized in that: The drug is an injectable preparation made from a phosphate buffer solution with a physiological concentration of pH 7.4.

Citation Information

Patent Citations

  • Novel glucagon like peptide analogs, composition, and method of use

    CN103124739A

  • Stabilized insulinotropic peptides and methods of use

    EP2590997A2